- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06414603
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy (ACES-EMB)
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy (ACES-EMB)
This is an open label Comparative Effectiveness Research (CER) study in which patients will be randomized at the site level to Prospera surveillance or EMB surveillance in a 2:1 ratio (Prospera to EMB) at each site.
Subjects will be enrolled into the study while under evaluation for heart transplantation or on the transplant waiting list prior to heart transplantation. All subjects will follow the center's standard of care surveillance schedule from transplant through 4 weeks post-transplantation. EMB during this phase is expected to occur roughly weekly or bi-weekly.
Study group assignment will take place at randomization. Subjects will be randomized 30 days (± 10 days) post-transplant to Prospera surveillance versus EMB surveillance in a 2:1 ratio. Rejection surveillance (Prospera Group and EMB Group) will be performed at times corresponding to the institutional standard of care schedule for rejection surveillance.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All subjects will undergo standard of care assessments for rejection monitoring in addition to Prospera testing and/or EMB in accordance with each site's clinical care protocols and at the discretion of the treating clinician. Quality of life questionnaires will be completed at week 4, month 6 and month 12 post-transplant.
Study Group: Prospera (dd-cfDNA) Surveillance Group Subjects are required to undergo Prospera testing at times corresponding to the institution's graft surveillance schedule. Prospera test results will be provided to the clinical team. Prospera cfDNA level < 0.15% will be interpreted as low risk for acute rejection (AR). Prospera cfDNA ≥ 0.15% will be interpreted as increased risk for AR and may be followed by EMB to rule out AR at the discretion of the treating clinicians. All other standard of care modalities for assessing AR can be used at the discretion of the treating clinicians at any time throughout the study. As per standard of care, in subjects with clinical signs or symptoms of rejection, a for cause EMB can be done per the clinical team's discretion at any time during the study.
Control Group: EMB Surveillance Group Subjects will undergo surveillance EMB per the institution's standard clinical care. Biopsy interpretation will be per the institutional pathologist using international guidelines for grading of acute cellular or antibody-mediated rejection. Subjects will also have Prospera testing performed at the time of surveillance EMB for the purpose of measuring concordance between dd-cfDNA surveillance testing and surveillance EMB; Prospera results will not be returned to investigators for subjects in the EMB surveillance group.
Subjects in both the Prospera and EMB Surveillance Groups will have Prospera blood draws performed at the time of any for cause EMB. Results of Prospera testing performed in conjunction with for cause EMB will not be returned to investigators or subjects.
Blood samples for exploratory mechanistic endpoints (miRNA) will be obtained at the time of each Prospera or EMB surveillance visit and at the time of any for cause EMB.
The study period will be during the first 12 months post-transplant.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kiara Stoddard
- Phone Number: (650) 249-9090
- Email: ACES@natera.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or older at the time of signing informed consent.
- Undergoing transplant evaluation or currently on the heart transplant waiting list and expected to receive a heart transplant.
- Able to read, understand and provide written informed consent. If the patient is unable to sign informed consent, a legally authorized representative (LAR) can consent on behalf of the patient.
- Able and willing to comply with the study visit schedule, study procedures and study requirements.
Exclusion Criteria:
- Concurrent multiple solid organ or tissue transplants.
- Prior history of any organ or cellular transplantation.
- Planned use of other commercially available or investigational cfDNA or gene expression profile assays for rejection surveillance.
- Pregnant.
- Hemodynamically unstable or other serious medical condition that may adversely affect the subject's ability to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prospera Surveillance Cohort
Subjects are required to undergo Prospera testing at times corresponding to the institution's graft surveillance schedule. Prospera test results will be provided to the clinical team. Prospera cfDNA level < 0.15% will be interpreted as low risk for acute rejection (AR). Prospera cfDNA ≥ 0.15% will be interpreted as increased risk for AR and may be followed by EMB to rule out AR at the discretion of the treating clinicians. All other standard of care modalities for assessing AR can be used at the discretion of the treating clinicians at any time throughout the study. As per standard of care, in subjects with clinical signs or symptoms of rejection, a for cause EMB can be done per the clinical team's discretion at any time during the study. |
The Prospera™ test is a non-invasive test intended to detect and quantify the fraction of donor-derived cell-free DNA (dd-cfDNA) to supplement management and surveillance of allograft rejection in patients who have undergone organ transplantation. It employs Next Generation Sequencing (NGS), which is performed on cell-free DNA (cfDNA) that is extracted from the patient's plasma to discriminate between the patient's DNA and the solid organ-allograft DNA. In study 23-069-TRP, the Prospera test is indicated for heart allograft rejection surveillance in lieu of surveillance endomyocardial biopsy. Prospera results should be considered together with clinical evaluations and other diagnostic testing or imaging results. Prospera will be run as a centralized laboratory developed test that is developed and validated under Design Controls. The test will be run within Natera's CLIA-certified and CAP-accredited laboratory. |
No Intervention: Endomyocardial Biopsy Surveillance Cohort
Subjects will undergo surveillance EMB per the institution's standard clinical care. Biopsy interpretation will be per the institutional pathologist using international guidelines for grading of acute cellular or antibody-mediated rejection. Subjects will also have Prospera testing performed at the time of surveillance EMB for the purpose of measuring concordance between dd-cfDNA surveillance testing and surveillance EMB; Prospera results will not be returned to investigators for subjects in the EMB surveillance group. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Clinical Endpoint
Time Frame: 12 months
|
Incidence of the composite endpoint defined as the first occurrence of treated rejection with graft dysfunction*, treated rejection without graft dysfunction, graft dysfunction, retransplantation, and/or death. Clinical endpoints are defined as follows:
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Michael Olymbios, MD, Natera, Inc.
- Study Chair: Josef Stehlik, MD, University of Utah
- Study Chair: Palak Shah, MD, Inova Schar Heart and Vascular
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 23-069-TRP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Transplant Failure and Rejection
-
Juan Francisco Delgado JimenezFundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIActive, not recruitingAntibody-mediated Rejection | Heart Transplant Rejection | Transplant FailureSpain
-
Natera, Inc.WithdrawnHeart Transplant Failure and Rejection
-
Baylor Research InstituteActive, not recruitingHeart Transplant Failure and RejectionUnited States
-
University of UtahNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingHeart Transplant Failure and RejectionUnited States
-
Ronald WittelesWithdrawnHeart Transplant Failure and Rejection | Allosensitization
-
Hopital FochRecruitingLung Transplant Rejection | Lung Transplant Failure | Lung Transplant; Complications | Lung Transplant Failure and RejectionFrance
-
Ronald WittelesCompletedHeart Transplant Failure and Rejection | AllosensitizationUnited States
-
Columbia UniversityVeloxis PharmaceuticalsActive, not recruitingRenal Transplant Rejection | Kidney Transplant Failure and RejectionUnited States
-
Charite University, Berlin, GermanyActive, not recruitingKidney Transplant Rejection | Antibody-mediated Rejection | Kidney Transplant FailureGermany
-
Baylor Research InstituteActive, not recruitingCompliance, Patient | Graft Failure | Heart Transplant RejectionUnited States
Clinical Trials on The Prospera™ Test
-
Foundation for Innovative New Diagnostics, SwitzerlandBotswana Harvard AIDS Institute PartnershipCompletedCorona Virus InfectionBotswana
-
University of AlbertaNatera, Inc.; One LambdaRecruitingHeart Transplant RejectionUnited States, Canada, Spain, Australia, Austria, Czechia, Italy, Poland
-
Rambam Health Care CampusThe Baruch Padeh Medical Center, PoriyaRecruitingCOVID-19 | MIS-C Associated With COVID-19Israel
-
Biruni UniversityRecruiting
-
U.S. Wound RegistryUnknownBurns | Diabetic Foot Ulcers | Pressure Ulcer | Surgical Wound Dehiscence | Venous Stasis Ulcer | Other Types of Chronic Non Healing WoundsUnited States
-
Energenx Medical LTD.Recruiting
-
Gazi UniversitySeroxo LtdCompletedInfections | Sepsis | Septic ShockTurkey
-
Proteocyte Diagnostics Inc.The University of Texas Health Science Center, Houston; University of Alabama... and other collaboratorsRecruitingMouth DiseasesUnited States